Inclisiran Wins on LDL; Cardio Salaries Climb; Is Keto Healthy?
Recent developments of interest in cardiovascular medicine
Novel twice-a-year cholesterol drug inclisiran beat statins alone for LDL lowering, according to topline results from the phase III ORION-11 trial announced ahead of presentation at the European Society of Cardiology meeting. Forbes notes that CV outcomes and price will be key, and Endpoints News further lays out the possible market shakeup.